News

US-based Alexion Pharmaceuticals has started a single, multinational, placebo-controlled trial designed to assess the safety and efficacy of eculizumab (Soliris) in patients with relapsing neuromyelitis optica (NMO), a life-threatening, ultra-rare neurologic disorder. Primary objective of the...

The National Institute for Health and Care Excellence (NICE) in the UK has issued its final health technology appraisal recommending afatinib as a first-line treatment option for patients with advanced or metastatic non-small cell lung cancer (NSCLC). ...

US-based drug maker Pfizer has confirmed that it has contacted AstraZeneca seeking to renew discussions over a possible £60bn takeover. The discussions are regarding developing a proposal by both companies that could be recommended to their...

Eli Lilly has obtained US Food and Drug Administration approval for its Cyramza (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine or...

US-based biopharmaceutical firm AbbVie has started a global Phase III clinical trial of an investigational oral poly (adenosine diphosphate -ribose) polymerase (PARP) inhibitor 'veliparib (ABT-888)' in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer...

Pleasanton, CA, USA, 21 February 2014 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a licensing agreement with Sysmex Inostics GmbH for its emPCR portfolio of patents. Under the terms of the licensing agreement, Roche grants Sysmex Inostics...

Copenhagen, Denmark, February 21, 2014 - Today announced that it has entered an exclusive license agreement with a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada, for small molecule compounds targeting an...